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T-cell activation and maturation in vitro, but does not
confer an anergic or suppressive phenotype
Giovanni A. M. Povoleri1 , Sylvine Lalnunhlimi∗1, Kathryn J. A. Steel∗1,
Shweta Agrawal1, Aoife M. O’Byrne1, Michael Ridley1,
Shahram Kordasti2, Klaus S. Frederiksen3, Ceri A. Roberts1
and Leonie S. Taams1
1 Centre for Inflammation Biology and Cancer Immunology (CIBCI), Dept of Inflammation
Biology, School of Immunology & Microbial Sciences, King’s College London, London, UK
2 Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King’s College
London, London, UK
3 Global Drug Discovery, Diabetes Research, Novo Nordisk A/S, Ma˚løv, Denmark
TNF-blockade has shown clear therapeutic value in rheumatoid arthritis and other
immune-mediated inflammatory diseases, however its mechanism of action is not fully
elucidated.We investigated the effects of TNF-blockade on CD4+ T cell activation,matura-
tion, and proliferation, and assessed whether TNF-inhibitors confer regulatory potential
to CD4+ T cells. CyTOF and flow cytometry analysis revealed that in vitro treatment of
human CD4+ T cells with the anti-TNFmonoclonal antibody adalimumab promoted IL-10
expression in CD4+ T cells, whilst decreasing cellular activation. In line with this, anal-
ysis of gene expression profiling datasets of anti-TNF-treated IL-17 or IFN-γ-producing
CD4+ T cells revealed changes in multiple pathways associated with cell cycle and pro-
liferation. Kinetics experiments showed that anti-TNF treatment led to delayed, rather
than impaired T-cell activation and maturation. Whilst anti-TNF-treated CD4+ T cells
displayed some hyporesponsiveness upon restimulation, they did not acquire enhanced
capacity to suppress T-cell responses or modulate monocyte phenotype. These cells how-
ever displayed a reduced ability to induce IL-6 and IL-8 production by synovial fibroblasts.
Together, these data indicate that anti-TNF treatment delays human CD4+ T-cell activa-
tion, maturation, and proliferation, and this reduced activation state may impair their
ability to activate stromal cells.
Keywords: adalimumab  CD4+ T cells  CyTOF  interleukin-10  TNF inhibitor
 Additional supporting information may be found online in the Supporting Information sectionat the end of the article.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory condition,
characterised by synovial inflammation and hyperplasia, as well
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as autoantibody production in the majority of cases. The disease
can lead to debilitating bone and cartilage destruction, which
can result in severe disability and is associated with premature
mortality [1].
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The pathophysiology of the disease is still not fully understood.
It is believed that CD4+ T cells play a key role in RA pathogen-
esis; however, therapies specifically targeting CD4+ T cells have
not entered clinical use due to limited efficacy [2]. Nonetheless,
immunological cross-talk between CD4+ T cells and other immune
or stromal cells is an important factor for established RA dis-
ease [3]: CD4+ T cells can stimulate monocytes, macrophages, and
fibrobrast-like synoviocytes to secrete various pro-inflammatory
cytokines [4]. In turn, upon encounter with synovial monocytes,
macrophages, or fibroblasts, CD4+ T cells can secrete multiple
cytokines including IFN-γ, IL-17, and TNF [5–8], which can over-
come negative regulators of inflammation such as IL-10, thus cre-
ating a predominant pro-inflammatory environment [9].
Multiple pro-inflammatory cytokines detected in RA synovium
have been identified as therapeutic targets including IL-1, IL-6,
and TNF [10]. Several TNF-inhibitors have been engineered for
the treatment of RA, amongst them is adalimumab (ADA), a fully
human anti-TNF monoclonal antibody [11]. TNF-inhibitors have
shown demonstrable clinical success, however, loss of efficacy over
time is observed and approximately one-third of patients are or
become unresponsive to treatment. The reasons for this remain
unclear [12] and it is currently not possible to reliably predict
which patients will not respond [13, 14]. A better understanding
of the mechanisms of action of TNF inhibition may help shed light
on these issues.
Our lab recently demonstrated that adalimumab treatment led
to an increase in the proportion of CD4+ T cells that express
the anti-inflammatory cytokine IL-10, both ex vivo and in vitro
[15, 16]. This increase occurred in T cell populations that co-
expressed pro-inflammatory cytokines such as IFN-γ, IL-17, TNF-α,
or GM-CSF, and was independent of Tregs. In this study, we
further investigated the effects of TNF-blockade on CD4+ T-cell
activation, maturation, proliferation and assessed whether TNF-
inhibitors may confer regulatory potential to CD4+ T cells.
Results
ADA treatment leads to IL-10 induction in multiple
CD4+ T cell subsets
To evaluate the effect of ADA treatment on IL-10 induction in
pro-inflammatory populations of CD4+ T cells, we performed
mass cytometry (CyTOF) to obtain an unbiased, single-cell, multi-
dimensional analysis of IL-10 expression among different popu-
lations of cytokine producing cells. CD4+ T cells were stimulated
with anti-CD3 and anti-CD28 (aCD3/CD28) mAb for 3 days in
the absence or presence of 1 µg/mL of ADA followed by 3 h of
PMA/ionomycin stimulation in the presence of GolgiStop. Visual
stochastic neighbour embedding (viSNE) was used to create a
map of CD4+ T cells; cells were automatically arranged along t-
distributed stochastic neighbour embedding (t-SNE) axes based on
phenotypic similarity of each cell [17]. This unsupervised viSNE
analysis visualised multiple clusters of IL-10, IFN-γ, and IL-17 pro-
ducing CD4+ T cells (Fig. 1A). While ADA treatment did not affect
the expression of IFN-γ and IL-17, an increase in intensity and
density of IL-10+ clusters was observed (Fig. 1A). Furthermore,
our analysis confirmed our previous data [16] that ADA affected
IL-10 expression in multiple clusters of CD4+ T cells, including in
clusters of IFN-γ and IL-17 expressing cells (Fig. 1B). To identify
these distinct populations (or nodes) of cytokine producing T cells,
based on the differential expression of the markers used for the
tSNE analysis, we performed a spanning-tree progression analy-
sis of density-normalised events (SPADE) [18]. SPADE analysis
resolved CD4+ T cells into 100 sub-populations, each character-
ized by a different expression profile (Fig. 1C).
Marker enrichment modelling (MEM) [19] was performed to
distinguish the IL-10 producing populations by quantifying protein
enrichment values within the SPADE nodes (Supporting Informa-
tion Fig. 1A). MEM analysis allowed the identification of five IL-10
producing populations with an IL-10 MEM enrichment score ≥
+2.5 in the ADA condition (Supporting Information Fig. 1A, indi-
cated by node numbers in bold). To increase resolution and better
discriminate the different IL-10 producing sub-populations, viSNE
and SPADE analysis were also run on gated CD4+CD45RO+ cells
(Supporting Information Fig. 1B–E), revealing 50 sub-populations
(Supporting Information Fig. 1E). MEM analysis of memory CD4+
T cells identified 12 IL-10 producing populations (Supporting
Information Fig. 1F). These analyses confirmed that culturing
CD4+ T cells with ADA increased the expression of IL-10 in multi-
ple distinct CD4+ T cell subsets, including those expressing IL-17
and IFN-γ. Furthermore, ADA treatment led to expansion of IL-10
producing populations (e.g. CD4+ T cell nodes 65 and 77, Fig. 1C),
while induction of IL-10 in some cells was revealed by focusing
the clustering analysis on the “enriched” CD4+CD45RO+ cells (e.g.
nodes 16 and 38, Supporting Information Fig. 1E). Finally, MEM
analysis revealed that ADA treatment did not result in a dramatic
change in the broad phenotype of IL-10+ populations, as compared
to IL-10+ cells in cultures where no ADA was present (Fig. 1D and
Supporting Information Fig. 1G).
Since adalimumab is known to bind to the transmembrane
form of TNF (mTNF) [20], we sought to determine whether
there was an association between IL-10 producing cells and ADA-
bound cells. We assessed the binding of adalimumab (an IgG1
human antibody) on CD4+ T cells after 3 days of culture, using a
fluorochrome-conjugated mouse anti-human IgG Fc antibody. We
found little expression of mTNF on CD4+ T cells (Supporting Infor-
mation Fig. 1H), which was reflected by only a small proportion
of CD4+ T cells positive for surface bound human IgG in cultured
samples treated with ADA for up to 3 days (Fig. 1E and Supporting
Information Fig. 1I). Furthermore, when we specifically analysed
the IL-10+ CD4+ T cells, a minority (on average 5.9%) of IL-10+
CD4+ T cells stained positive for human IgG; vice versa, on aver-
age only 14.7% of hIgG+ cells expressed IL-10 (Fig. 1F) following
treatment with adalimumab. These data suggest there is no direct
correlation between ADA binding to the surface of CD4+ T cells
and IL-10 expression at day 3.
We also investigated the expression of TNFR1 and TNFR2 on
IL-10 expressing cells. While we were unable to detect TNFR1 on
CD4+ T cells after culturing cells in the absence or presence of ADA
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 1. Adalimumab (ADA) treatment enhances IL-10 production in multiple subsets of cytokine producing CD4+ T cells. (A) viSNE plots of
CyTOF data from CD4+ T cells stimulated for 3 days with aCD3/CD28mAb, and 3 h of PMA/Ionomycin, in the absence (top row) or presence (bottom
row) of ADA; cells were clustered using surface and intracellular markers. Shown are heatmaps for expression of indicated markers. (B) Overlay of
IL-10+ (red), IFN-γ+ (orange), and IL-17+ (green) T cells on viSNEmap of CD4+ T cells (blue) showing the overlap of cells either expressing IL-10 alone
or in combination with other cytokines in the absence or presence of ADA; (C) 2D minimum spanning tree (SPADE) derived from viSNE analysis
showing population nodes of CD4+ T cells either cultured in the absence (left panel) or presence (right paneI) of ADA. Node size represents cell
number, and colour IL-10 median intensity. Grouped together are IL-17+ (circled in green) and IFN-γ+ (circled in orange) nodes. Numbered nodes
in C represent IL-10+ nodes identified from Supporting Information Fig. 1A. (D) Correlation matrix showing median expression of markers from
IL-10+ nodes from 1C and Supporting Information Fig. 1A. (E) Representative flow cytometry plot showing frequencies of CD4+ T cells stained for
IL-10 and hIgG at day 3 of stimulation with aCD3/CD28 mAb, in the absence or presence of ADA, and (F) cumulative data showing the frequency
of hIgG+ cells within total IL-10+ CD4+ T cells (left) and IL-10+ CD4+ T cells within total hIgG+ cells (right). Bars show mean ± SEM of results from
six independent experiments using n = 10 distinct donors. Data analysed by two-tailed paired Wilcoxon test.
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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for 3 days (data not shown), we found a significantly increased
frequency of TNFR2+ cells among IL-10+ compared to IL-10−
cells, however this effect was anti-TNF treatment independent
(Supporting Information Fig. 1J).
ADA treatment leads to a long-term induction of IL-10
expression in CD4+ T cells
To determinewhether the effect of ADA treatment on IL-10 expres-
sion in the different populations of CD4+ T cells persists over time,
we cultured the cells for up to two rounds of aCD3/CD28 mAb
stimulation in the absence or presence of ADA and determined
IL-10+ cell frequencies by flow cytometry. We observed a signif-
icant increase in IL-10+ cell frequencies in ADA-treated cells for
up to 7 days, including in IFN-γ− and IL-17-expressing popula-
tions (Fig. 2A and B, and Supporting Information Fig. 2A and B).
Following a second round of aCD3/CD28 mAb stimulation, ADA-
treated cells still maintained higher frequencies of IL-10+ cells up
to day 14, compared to the control group. Furthermore, a second
dose of ADA at restimulation did not further increase IL-10 fre-
quencies, compared to cells that received ADA at the beginning
of cell culture only (Fig. 2B). Finally, we found no significant dif-
ference in cell death upon culture of CD4+ T cells with ADA over
time (Supporting Information Fig. 2C). These data suggest that
ADA treatment leads to a long-term induction of IL-10 expression
in CD4+ T cells without inducing cell death.
In vitro ADA treatment delays CD4+ T cell activation,
maturation, and proliferation
To determine the effect of ADA treatment on early T cell phe-
notypic changes, we performed CyTOF analysis of CD4+ T cells
stimulated for 3 days in the absence or presence of ADA, with-
out PMA/Ionomycin. Although there was heterogeneity in cellu-
lar phenotype among donors following stimulation, 13 of the 28
markers included in the analysis were commonly downregulated
by ADA (Fig. 3A and Supporting Information Fig. 3A). Of these
markers, a number were associated with cellular activation and
maturation including CD45RO, CD27, CD28, and CD95 (Fig. 3A
and B).
In addition, we analysed previously generated gene expres-
sion profiling datasets of CD4+ T cells cultured in the absence
or presence of ADA, which were then sorted for IL-17-secreting
(Th17) or IFN-γ-secreting (Th1) cells. Comparison of the two
datasets revealed that 220 genes were commonly regulated by
TNF-blockade: 85 up-regulated and 128 down-regulated genes
in both Th1 and Th17 cells, and seven genes that were differ-
entially regulated in Th17 vs Th1 cells (Supporting Information
Fig. 3B). We performed Gene Ontology (GO)-FAT Biological Pro-
cess enrichment analysis on the commonly differentially expressed
(with q  0.05) genes and found that within the top 30 GO terms
revealed by our analysis, 10 were associated with cell cycle and
division (Fig. 3C), suggesting an effect of ADA on genes associated
with these pathways. These data thus pointed to ADA acting as a
modulator of cellular activation, maturation, and proliferation of
CD4+ T cells.
To directly test this hypothesis, we stimulated CD4+ T cells with
aCD3/CD28 mAb for 7 days in the absence or presence of adali-
mumab and evaluated by flow cytometry the changes in expression
of activation markers CD25 and CD69 as well as proliferation, as
measured by expression of Ki67 and CellTrace Violet dye dilution
(Fig. 4A and B). ADA treatment led to a significant decrease in the
frequency of CD25+ cells at day 4. By day 7, the decrease in CD25+
cells was less pronounced, suggesting this effect might be due to
delayed activation rather than blocked activation. The frequency
of CD69+ cells, an early activation marker, was not consistently
higher or lower in ADA treated cells, at either day 4 or day 7. ADA
treatment also resulted in a small but significant decrease in T-cell
proliferation, as determined by CellTrace Violet dye dilution at
both day 4 and day 7, and Ki67 expression at day 4.
Changes in activation and proliferation following anti-TNF
treatment could lead to a variation in how CD4+ T cells mature
and differentiate. Indeed, upon anti-TNF treatment, a signifi-
cantly higher proportion of na¨ıve CD4+CD45RA+CD45RO− cells
was present at day 4, but not day 7, in samples treated with
ADA. Concomitantly, a significantly lower percentage of memory
CD4+CD45RA−CD45RO+ cells was observed in the presence of
ADA, at both day 4 and day 7 (Fig. 4C and D).
ADA treatment does not confer suppressive ability to
CD4+ T cells
We investigated whether preconditioning of CD4+ T cells with
anti-TNF mAb could confer anergy or suppressive ability to the
cells. We first assessed whether ADA pretreatment rendered the
cells hyporesponsive to restimulation. To this end, CD4+ T cells
were initially cultured with aCD3/CD28 mAb for 4 days in the
absence (no ADA pretreatment) or presence (ADA pretreatment)
of adalimumab; the cells were then washed and rested for two
days, followed by 7 days of stimulation to test their proliferative
response and IFNγ expression. CD4+ T cells pretreated with ADA
showed a small, but consistent decrease in proliferation as well as
a significant reduction in IFN-γ+ frequencies and secretion upon
restimulation, compared to cells that were pretreated without ADA
(Fig. 5).
Next, we determined whether pre-treatment with ADA led cells
to become suppressive by co-culturing ADA pretreated or control
pretreated CellTrace Far Red (CTFR) labelled cells with responder
CellTrace Violet (CTV) labelled cells (Fig. 6A). To this end, CD4+
T cells were initially cultured with aCD3/CD28 mAb for 4 or 7
days in the absence (no ADA pre-treatment) or presence (ADA pre-
treatment) of adalimumab; the cells were then washed and rested
for two days, followed by testing of the proliferative response and
cytokine production of the responder cells. A significant reduction
in proliferative capacity and IFN-γ+ cell frequencies was observed
in responder CD4+ T cells that were co-cultured with CD4+ T cells
that had previously been treated with ADA (Suppressors (ADA)),
however a similar effect was observed when responder cells were
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 2. Adalimumab (ADA) treatment has a prolonged effect on IL-10 production by CD4+ T cells. (A) Representative flow cytometry plot showing
frequencies for IL-10 in CD4+ T cells at day 4 of stimulation with aCD3/CD28 mAb, in the absence (left) or presence (right) of ADA, in either total
CD4+ cells (top row) or within either IFN-γ+ (middle row) or IL-17+ (bottom row) cells; (B) cumulative plots showing the frequencies of populations
from (A) at day 0, 4, and 7 of stimulation with aCD3/CD28 mAb, in the presence (open triangle) or absence (filled square) of ADA. At day 7, cells
received a second round of aCD3/CD28 mAb stimulation and some cells received a second dose of ADA (open circle). Cumulative data from six
independent experiments using n = 8 distinct donors (data for each time points not available for all donors). Data analysed by either paired
Wilcoxon (day 4 and day 7) or Friedman multiple comparisons (day 10 and day 14) tests. Only significant p-values are reported.
co-cultured with CD4+ T cells treated without ADA (Suppressors
(No ADA)) (Fig. 6B). Thus, there was no differential effect in
the suppressive activity of cells that had been pretreated with or
without ADA and depletion of Tregs (open symbols) did not alter
this result. Furthermore, no significant differences were observed
in the frequencies of TNF-α+ or IL-10+ responder T cells upon
co-culture (Fig. 6B).
ADA pretreated CD4+ T cells do not differentially
modulate monocyte activation
Since pretreatment of CD4+ T cells with ADA did not lead to the
acquisition of a specific T cell-suppressive phenotype, we evalu-
ated whether anti-TNF-treated T cells might affect monocyte phe-
notype and function. To this end, we cultured CD4+ T cells for 3
days with aCD3/CD28 mAb in the absence or presence of ADA;
cells werewashed and rested, and then added into co-cultures with
monocytes for 40 h in the absence (for phenotypic analysis) or
presence (for cytokine analysis) of LPS. No significant differences
in monocyte expression of HLA-DR, CD80, CD86, CD40, or CD163
were observed when monocytes were co-cultured with ADA pre-
treated T cells compared to control pretreated cells (Supporting
Information Fig. 4). In terms of LPS-induced cytokine production,
co-culture with ADA pre-treated T cells led to a significant reduc-
tion in monocytic IL-6 and IL-8 production compared to the no
T cell control; when compared to co-culture with control-treated
T cells, LPS-induced production of IL-6, but not IL-8, was slightly
lower (Fig. 7A). Collectively, these data show that a specific regu-
latory effect of ADA-treated CD4+ T cells on monocyte activation
is seen only in terms of IL-6 production in response to LPS.
ADA pretreated CD4+ T cells induce lower
pro-inflammatory cytokine production by fibroblasts
Finally, we sought to investigate whether ADA pretreated T cells
could affect RA fibroblast function. To this end, we stimulated
CD4+ T cells for 3 days in the absence or presence of adalimumab
and then washed, rested, and co-cultured the cells with RA fibrob-
lasts for 3 days before evaluating cytokine production post co-
culture. Co-culture of RA fibroblasts and T cells was required to
obtain detectable amounts of IL-6 and IL-8, independent of the pre-
treatment condition (Fig. 7B). However, co-culture of fibroblasts
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 3. Adalimumab (ADA) treatment leads to negative modulation of multiple CD4+ T cell markers. (A) Cumulative plot showing the mean
intensity of themarkers, as evaluated by CyTOF, commonly downregulated by ADA treatment in CD4+ T cells stimulated for 3 dayswith aCD3/CD28
mAb (results from three independent experiments using n = 3 distinct donors); (B) representative viSNE plots of CD4+ T cells stimulated for 3
days with aCD3/CD28 mAb in the absence (top row) or presence (bottom row) of ADA; cells were clustered using surface and intracellular markers.
Shown are heatmaps for expression of indicated markers (results from three independent experiments using n = 3 distinct donors); (C) list of
Gene Ontology (GO)-FAT Biological Processes, subjected to enrichment analysis, from commonly differentially expressed genes (q  0.05) between
two differential gene lists generated from microarray data of CD4+ T cells stimulated for 3 days with anti-CD3 mAb and monocytes (2:1 ratio) in
the presence or absence of ADA and then sorted for IL-17 secreting (“Th17”, n = 9 donors) or IFN-γ secreting (“Th1”, n = 8 donors) CD4+ T cells,
representing all genes significantly up- or down-regulated upon TNF-blockade at the 5% false discovery rate (FDR). Data from five independent
experiments. Shown are the number of genes involved in the term (count), percentage of involved genes within the total number of genes (%),
Modified Fisher’s Exact p value, EASE Score (P value), and Benjamini corrected p value (Benjamini). The top 30 of 349 total GO terms (ordered by
Benjamini corrected p value) are shown.
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 4. Adalimumab (ADA) treatment leads to delayed activation, proliferation and maturation of CD4+ T cells. (A, B) Representative flow
cytometry plots (A, day 4) and cumulative data (B) showing percentages of CD25+, CD69+, proliferating and Ki67+ CD4+ T cells at day 0, day 4,
and day 7 post stimulation with aCD3/CD28 mAb in the absence (filled square) or presence of ADA (open triangle). Data from ten independent
experiments using n = 14–17 donors; (C, D) representative flow cytometry plots (C) and cumulative data (D) showing percentage of CD45RA+ and
CD45RO+ CD4+ T cells at day 0, day 4, and day 7 post stimulation with aCD3/CD28 mAb in the absence (filled square) or presence of ADA (open
triangle). Data from four independent experiments, using n = 8 donors. All data analysed by Wilcoxon paired test (day 4 and day 7). Significant
p-values are reported.
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 5. Adalimumab (ADA) pre-treatment leads to minor hyporesponsiveness of CD4+ T cells. (A, B) Representative flow cytometry plots (A) and
cumulative plots (B) for proliferation and IFN-γ staining of CD4+ T cells pretreated for 4 days with aCD3/CD28 mAb in the absence (filled square) or
presence (open triangle) of ADA and then re-stimulated for 7 days with aCD3/CD28 mAb stimulation; (C) cumulative plot showing IFN-γ secretion
from B. Data from five independent experiments using n = 7 donors and analysed by Wilcoxon paired test. Significant p-values and lower/upper
limits of detection (dashed lines) for cytokine quantification are reported.
with ADA pretreated cells led to significantly lower production of
IL-6 and IL-8 compared to co-culture with cells pretreated without
ADA (Fig. 7B). Unexpectedly, this effect was independent of IL-10
since the addition of blocking antibodies to IL-10 and IL-10R did
not reverse the reduction in pro-inflammatory cytokines (Fig. 7C).
Discussion
Expanding on our previous work [16], the single cell CyTOF
analysis presented here demonstrates that adalimumab treatment
affects multiple CD4+ T cell subsets leading to both a boost and
expansion of IL-10 producing cells, including in cells actively
expressing proinflammatory cytokines like IFN-γ and IL-17. We
found that the effect of adalimumab on IL-10 production per-
sisted over our 2-week culture period, however a repeat dose of
adalimumab did not significantly enhance the production of IL-10
compared to cells receiving only one dose. We found no associa-
tion between IL-10 producing cells and binding of adalimumab to
the CD4+ T cell surface, suggesting that the effect of anti-TNF on
modulation of IL-10 expression occurs independently of binding
to transmembrane TNF, which is expressed at very low levels on
the surface of CD4+ T cells.
The increased expression of the anti-inflammatory cytokine
IL-10, pairedwith the negativemodulation ofmultiplemarkers fol-
lowing stimulation, led us to evaluate whether TNF signalling inhi-
bition affected CD4 T-cell activation. While a downregulation of
activation marker CD25 was found following anti-TNF treatment,
variation in CD69 expression did not show a consistent trend.
CD69, however, is an early and short-term activation marker,
compared to the “late” activation marker CD25 [21]. Given we
only assessed T-cell activation at days 4 and 7, it is possible that
any initial modulatory effects on CD69 expression had normal-
ized by then. Previous studies also showed that anti-TNF leads to
decreased T-cell activation, as demonstrated by variation of CD25
expression, in IBD [22, 23], ulcerative colitis [24], psoriasis [23],
and RA [25], while the effect on CD69 was more variable [23, 25].
Some of these studies showed decreased proliferation following
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 6. Adalimumab (ADA) pretreatment does not confer a suppressive phenotype to CD4+ T cells. (A) Representative flow cytometry plots
showing gating strategy for co-cultures containing CellTrace Far Red (CTFR) labelled CD4+ T suppressor cells pretreated for 4 or 7 days with
aCD3/CD28 mAb in the absence (No ADA) or presence (ADA) of ADA and CellTrace Violet (CTV) labelled bulk CD4+ or CD4+CD25− responder cells
after they have been co-cultured for 4 or 7 days with aCD3/CD28 mAb; (B) cumulative plots showing percentages of proliferating, IFN-γ+, TNF-α+
and IL-10+ cells within either bulk CD4+ (filled symbols) or CD4+CD25− (open symbols) responder cells. Bars show mean ± SEM of results from
three independent experiments using n = 5 donors and analysed by Friedman multiple comparisons test. Significant p-values are reported.
TNF-blockade [22, 24], while one study reported an increased
proliferative response in patients upon TNF-blockade [23]. These
studies however evaluated the effect of anti-TNF on T-cell acti-
vation and proliferation in the context of whole PBMC cultures
or mixed lymphocyte reactions, where the TNF inhibition affects
both the T cell and APC compartments. Indeed, CD4+ T cells
co-cultured with monocytes from RA patients on TNF-inhibitors
showed decreased proliferation [26], with another study attribut-
ing this effect to the induction of regulatory macrophages in an
Fc dependent manner [20]. Our data show that anti-TNF drugs
can delay both T cell activation and proliferation in an APC inde-
pendent manner. Furthermore, we found that adalimumab treat-
ment led to a short-term skewing of the balance between na¨ıve
and memory CD4+ T cells towards the former, which normalised
over time. This delayed but eventually normalising effect on mat-
uration would be consistent with the reported lack of variation
in percentages of circulating memory T cell subsets in patients
receiving anti-TNF therapy for 1–3 months [23]. Finally, we did
not find a significant difference in cell death upon culture with
ADA over time, which is consistent with previously published data
that anti-TNF does not induce apoptosis in T cells or MLR [20].
Our data therefore suggest that TNF-blockade can exert direct
delaying effects on CD4+ T-cell activation, proliferation, and mat-
uration, but does not affect the long-term viability and ability of
T cells to respond to stimulation.
We have previously demonstrated that anti-TNF mediated
IL-10 induction in T cells is independent of Tregs [15, 16]. There
is no consensus on how TNF-blockade affects Tregs; studies have
reported an increase in expression of Foxp3 and/or suppressive
function of Tregs after neutralization of TNF [27–31], while other
studies showed that TNF signaling through TNFRII promoted
Treg expansion and function [32, 33] and therefore anti-TNF can
decrease Treg activity [34]. Our data show that culturing CD4+
T cells in the presence of adalimumab led to a small decrease in
Foxp3 and Helios expression accompanied by a limited reduction
in proliferation. We found a more pronounced effect on IFN-γ
expression and secretion upon re-stimulation, but did not find
evidence for profound T cell anergy. Furthermore, CD4+ T cells
that were pretreated with adalimumab, despite the increased
IL-10 production, did not show a significantly greater suppressive
ability, compared to control-treated cells, when co-cultured with
responder T cells. These data therefore suggest that TNF-blockade
does not confer a Treg-like phenotype or suppressive function to
CD4+ T cells.
We showed that anti-TNF pretreatment of CD4+ T cells did
not dramatically affect the capacity of the cells to modulate the
phenotype and function of monocytes, except for a small reduc-
tion in LPS-induced IL-6 production. Other studies have shown
that anti-TNF may affect the interaction between monocytes and
T cells leading to a more tolerogenic phenotype. It was shown
that adalimumab promoted binding between monocytes of RA
patients, which expresses high levels of mTNF, and TNF-RII-
expressing Tregs, leading to the expansion of the latter [35].
It was also shown that monocyte binding of the Fc region of
C© 2019 The Authors. European Journal of Immunology published by
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Figure 7. Adalimumab (ADA) pretreatment of CD4+ T cells leads to reduced inflammatory phenotype of fibroblasts post co-culture. (A, B) Cumu-
lative plots showing supernatant concentrations of IL-6 and IL-8 after either 40 h co-culture of monocytes in presence of LPS (A, n = 7) or after 3
days co-culture of fibroblasts (B, n = 14) with either no CD4+ T cells (grey circles), No ADA (black squares) or ADA (open diamonds) pretreated sup-
pressors; (C) cumulative plots showing supernatant concentrations of IL-6 and IL-8 post 3 days co-culture of fibroblasts with either No ADA (black
squares) or ADA (open diamonds) pretreated suppressors in the absence or presence of blocking anti-IL-10 and anti-IL10R antibodies or isotype
controls (n = 4). Bars show mean ± SEM of results from four (A), five (B), and two (C) independent experiments all analysed by pairwise Friedman
multiple comparisons test. Significant p-values and lower/upper limits of detection (dashed lines) for cytokine quantification are reported.
anti-TNF antibodies promoted the generation of regulatory
M2-like CD206+ macrophages, post co-culture with CD4+
T cells [20]. In our co-culture setting, where anti-TNF is limited to
the CD4+ T cell pretreatment stage, we found no overall variation
in the expression of costimulatory molecules on the monocytes
and only a limited effect on LPS-induced IL-6 production. These
data suggest that anti-TNF preconditioning of CD4+ T cells alone
is insufficient to significantly modulate monocyte phenotype
in vitro.
Synovial fibroblasts are particularly important in the context
of RA given their role in the active invasion of articular cartilage
and damage mediated by release of proinflammatory and matrix-
degrading mediators (reviewed in ref. [36]). TNF-α is a strong
inducer of fibroblast activation and is a key driver of inflammation
C© 2019 The Authors. European Journal of Immunology published by
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and joint destruction; systemic over-expression of human TNF
in vivo is sufficient to initiate chronic synovium inflammation,
cartilage destruction, and bone erosion, which can be ameliorated
by treatment with anti-TNF [37]. Interestingly, our data showed
that anti-TNF pre-treated CD4+ T cells have a reduced ability
to induce the production of proinflammatory mediators by RA
fibroblasts, which is independent of IL-10. This finding suggests
that anti-TNF pre-conditioning could prime CD4+ T cells to reg-
ulate fibroblast-driven inflammation, even after TNF inhibition is
no longer present.
Further work is required to investigate how TNF inhibition
therapy restrains the immune response in RA and in particular how
modulation of IL-10 expression contributes to this immunoregu-
lation. Furthermore, insight into the molecular mechanisms via
which TNF-blockade operates, both in maintaining IL-10 expres-
sion and regulating cellular activation and function, could identify
potential targets for novel therapeutic strategies.
Materials and methods
Cell isolation
Peripheral blood samples were obtained from healthy adult vol-
unteers. PBMCs were isolated by density gradient centrifugation
using Lymphoprep (Axis-Shield, Oslo, Norway). CD4+ T cells
and CD14+ monocytes were isolated by MACS using the CD4+
T cell Isolation Kit II and CD14 MicroBeads, respectively (Miltenyi
Biotec, Bergisch-Gladbach, Germany). Average purities were 96%
for both CD4+ T cells and CD14+ monocytes. For isolation of
CD4+CD25− T cells, CD4+ T cells were subsequently depleted
of CD25+ cells using CD25 MicroBeads II (Miltenyi Biotec). The
study was approved by the Bromley Research Ethics Committee
(06/Q0705/20), and written informed consent was obtained from
all participants.
CD4+ T cell culture
Cells were cultured at 37°C with 5% CO2 in RPMI 1640 medium
(Gibco) supplemented with 10% heat-inactivated fetal bovine
serum (Sigma) and 1% penicillin, streptomycin and L-glutamine
(all from Gibco). MACS-isolated CD4+ T cells were stimulated at
106/mL with 1.25 µg/mL of coated anti-CD3 (clone OKT3; BD
Biosciences) and 1 µg/mL of soluble anti-CD28 (clone CD8.2; BD
Biosciences) in the absence or presence of 1 µg/mL of adalimumab
(ADA, Abbott Laboratories, Chicago, USA) for up to 7 days. For
subsequent rounds of stimulation, cells were washed, counted,
and restimulated as described above.
Hyporesponsiveness assay
Bulk CD4+ T cells were cultured and stimulated as described above
for 4 days in the absence or presence of adalimumab (1 µg/mL).
Cells were washed and rested for 48 h at 37°C. Cells were
then labelled with CTFR or CTV; both at 1 µM, LifeTechnologies
(Carlsbad, USA, following manufacturer’s instructions) and stim-
ulated for 7 days with aCD3/CD28 mAb stimulation, as above.
Proliferation and IFN-γ production were measured by flow cytom-
etry and ELISA.
T cell suppression assay
Bulk CD4+ T cells were cultured and stimulated as described
above for either 4 or 7 days in the absence or presence of
adalimumab (1 µg/mL). Cells were washed and rested for 48 h at
37°C. Suppressor cells were then labelled with CTFR (1 µM) and
co-cultured with CTV (1 µM; both LifeTechnologies, Carlsbad,
USA) bulk CD4+ or CD4+CD25− T cells, as responders, at 1:0.5
(Responders:Suppressors) ratio for 4 or 7 days with either
standard aCD3/CD28 mAb stimulation or aCD3/CD28 beads
(GIBCO) at a 1:40 bead to cell ratio. Proliferation and IFN-γ fre-
quencies were measured in responder cells post co-culture by flow
cytometry.
Monocyte modulation assay
Bulk CD4+ T cells to be used for monocyte modulation were cul-
tured and stimulated as described above for 3 days in the absence
or presence of adalimumab (1 µg/mL). Cells were washed and
rested for 24 h. The pre-cultured CD4+ T cells were then co-
cultured with autologous CD14+ monocytes for 40 h at 1:0.5 ratio
(CD14+:CD4+) with soluble aCD3 mAb stimulation (100 ng/mL);
phenotype was assessed by flow cytometry. For evaluation of
cytokine production, LPS (50 ng/mL) was added for the duration
of the co-culture and supernatants collected at 40 h.
Fibroblast modulation assay
Bulk CD4+ T cells were cultured and stimulated as described above
for 7 days in the absence or presence of adalimumab (1 µg/mL),
with supplementation of 20 U/mL (Peprotech) of IL-2 on day 4.
Cells were washed and rested for 24 h at 37°C. Fibroblasts gen-
erated from RA patients’ knee replacement synovial tissue were
seeded in 96-well flat bottom plates at a density of 10 000/well in
DMEM, supplemented with 10% FCS, 1% penicillin/streptomycin,
2% L-glutamine (all from GIBCO), and 1 µg/mL Amphotericin
B/Fungizone (GIBCO) and allowed to adhere for 24 h. Twenty-
five thousand pre-cultured CD4+ T cells were added to the fibrob-
lasts and cultured in DMEM for 3 days with soluble aCD3 mAb
(100 ng/mL) with or without 10 µg/mL of anti-IL-10 (JES3-
19F1, Rat IgG2a, Biolegend) and anti-IL-10R (3F9, Rat IgG2a,
Biolegend) blocking antibodies or matching isotype control Ab
(RTK2758, Rat IgG2a, Biolegend). Supernatants were collected
post co-culture.
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Flow cytometry
To assess proliferation, CD4+ T cells were stained with either
1 µM of CTV or CTFR (both from Life Technologies), before stim-
ulation and culture. To assess intracellular cytokine expression
after cell culture, cells were stimulated for 3 h in the presence
of PMA (50 ng/mL, Sigma-Aldrich), ionomycin (750 ng/mL,
Sigma-Aldrich), and GolgiStop (BD Biosciences); GolgiPlug (BD
Biosciences) was additionally added for complete blocking of
TNF export when measuring expression of mTNF. Cells were
labelled with a fixable viability dye (LIVE/DEAD fixable dead cell
stains, ThermoFisher Scientific). Cells were subsequently washed
and stained extracellularly, followed by fixation with 2% PFA
(paraformaldehyde, Sigma-Aldrich), permeabilization using the
FOXP3 perm buffer (BioLegend). Cells were stained with various
combinations of the following fluorescently conjugated antibodies
(see Supporting Information Table 1). Stained cells were acquired
using a FACSCantoII or LSRFortessa (BD Biosciences); in most
experiments, 100 000 T cell events were recorded. All flow
cytometry data were analysed using FlowJo software (version
10, Tree Star, Ashland, USA). Representative CD4+ T cell gating
strategy is shown in Supporting Information Fig. 2. Guidelines for
the use of flow cytometry in immunological studies were adhered
to [38].
CyTOF staining and analysis
CD4+ T cells were isolated using MACS isolation and 3 × 106
cells labelled with metal conjugated antibodies for extracellu-
lar, intracellular, or intranuclear staining. Supporting Informa-
tion Table 2 shows the full list of both antibody panels (panel
1 for samples stimulated without PMA/Ionomycin; panel 2 for
samples stimulated for 3 h with PMA/Ionomycin before staining).
CyTOF-2 mass cytometer (Fluidigm) was used for data acquisition
and beads (Ce140) were used for normalization [39]. Data were
initially processed and analysed using Cytobank [39]. At least
350 000 events from the CD4+ or CD4+CD45RO+ gates (Support-
ing Information Fig. 1A) were equally sampled from all individuals
to perform automated clustering. Mass-cytometry complex data
was analysed using viSNE, in combination with SPADE, to iden-
tify distinct subpopulations [17, 18] using the following parame-
ters: for cytokine production evaluation: CCR6, CD62L, CD45RA,
CD95, IL-4, CCR4, CD161, CD103, TNFα, TIM3, PD1, Helios, IFNγ,
CCR7, Tbet, CTLA4, CD27, TGFβ, IL-17A, CD45RO, IL-2, GATA3,
IL-10, Foxp3, TIGIT, CXCR4, HLA-DR, LAG3, CD127; for marker
modulation by ADA treatment: CCR6, CD62L, CD45RA, CD95,
ICOS, CCR4, CD161, CD103, CD69, TIM3, PD1, Helios, CXCR3,
CCR7, Tbet, CTLA4, CD27, CD28, CD45RO, GATA3, IL-10, CD40L,
Foxp3, TIGIT, CXCR4, HLA-DR, LAG3, CD127. viSNE and SPADE
plots were generated using Cytobank (CA, USA). To quantify sim-
ilarities/differences among the nodes generated by SPADE and
identify the subsets among the clustered T cells, MEM for each
identified population was calculated [19]. Medians of the mark-
ers were hyperbolic arcsine (asinh) transformed (cofactor = 5).
Where indicated in the figure legend, figures were overlaid for
demonstration purposes.
Enzyme-linked immunosorbent assay (ELISA)
IFN-γ, IL-6, and IL-8 were measured in cell culture supernatants
using the ELISA MAX kits (BioLegend), according to manufac-
turer’s instructions. Microwell absorbance was read at 450 nm
using a Spark 10M microplate reader (TECAN, Austria).
Gene ontology analysis
Gene ontology analysis was performed on two datasets: one
based on CD4+ T cells stimulated for 3 days with anti-CD3
mAb and monocytes (2:1 ratio) in the presence or absence of
ADA and then FACS sorted for IL-17 secreting (Th17) cells
(GSE51540, as described in ref. [15]), and one based on CD45RO+
enriched CD4+ T cells (CD45RO microbeads, Miltenyi), cultured
as described above and then sorted for IFN-γ secreting CD4+
T (Th1) cells (GSE65054). RNA extraction, purification, integrity
analysis, and gene expression microarrays were carried out at
Novo Nordisk A/S (Ma˚løv, Denmark). Samples were run on
a Human Genome U219 Array plate (Affymetrix). Chips were
scanned and gene expression data were normalized using the
Robust Multi-array Average (RMA) algorithm and the Biocon-
ductor package “Affy” (http://www.bioconductor.org). Custom
CDF (chip definition file) from brainarray.mbni.med.umich.edu
was used. Gene expression profiling analysis was performed using
Qlucore Omics Explorer 3.0 software (Qlucore AB, Lund, Swe-
den). Two differential gene lists were generated from each set
of microarray data, representing all genes up/down-regulated
by TNF-blockade in IL-17-secreting (“Th17”) or IFN-γ-secreting
(“Th1”) CD4+ T cells at 5% false discovery rate (FDR). Ensembl
gene IDs from each gene list were compared using the online plat-
form Venny (http://bioinfogp.cnb.csic.es/tools/venny/). Com-
monly differentially expressed (q  0.05) genes were subjected
to Gene Ontology (GO)-FAT Biological Process enrichment analy-
sis using DAVID.
Statistical analysis
Statistical testingwas performedwith GraphPad Prism 7.0 (Graph-
Pad, San Diego, CA, USA). Data sets were tested using the appro-
priate non-parametric test as indicated in figure legends. p-values
< 0.05 were considered statistically significant.
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